Inhibitor Therapeutics, Inc. 8-K

What Happened

• Inhibitor Therapeutics, Inc. (INTI) announced that it entered into a Securities Purchase Agreement (SPA) reported on February 24, 2026 under which an institutional investor agreed to invest $3,000,000 in exchange for 12,000,000 shares of common stock and a warrant to purchase up to 7,000,000 additional shares (price: $0.25 per share and accompanying warrant). After the investor failed to complete funding and perform its obligations, the company initiated litigation against the investor on March 30, 2026. The February 24th Form 8-K included descriptions of the SPA and warrant as exhibits; the company said it will provide more litigation details in a later Form 8-K when available.

Key Details

• SPA terms reported Feb 24, 2026: 12,000,000 common shares and a warrant for up to 7,000,000 shares for $3,000,000 (implied $0.25 per share).
• Investor failed to fund the $3.0M investment and perform SPA obligations; multiple pre-litigation attempts to secure payment were made.
• Litigation was initiated by the company on March 30, 2026; additional information will be disclosed in future filings.

Why It Matters

• The planned $3.0M financing did not close, which affects the company’s expected cash inflows and any near-term financing plan tied to this SPA. Investors should watch for updates on the lawsuit and any replacement financing or cash-impact disclosures in future 8-Ks or SEC filings.
• If the financing had closed, it would have increased outstanding shares and potential dilution via the warrant; the outcome of the litigation will determine whether the company recovers funds or pursues alternative capital.